Abstract
Mice deficient for classical complement pathway (CCP) factor C4 are resistant to antibody and complement mediated experimental autoimmune myasthenia gravis (EAMG). Anti-C1q antibody administration before or following acetylcholine receptor immunization suppresses EAMG development by reducing lymph node cell IL-6 production and neuromuscular junction IgG, C3 and C5b-C9 deposition. This effect is achieved by treating mice with 10 µg of anti-C1q antibody, twice weekly for 4 weeks. Treatment with a higher amount of anti-C1q antibody gives rise to increased serum anti-acetylcholine receptor antibody, immune complex and C3 levels, facilitates kidney C3 and IgG deposits and thus reduces the treatment efficacy. C4 KO and anti-C1q antibody treated mice display normal immune system functions and intact antibody production capacity. Furthermore, CCP inhibition preserves alternative complement pathway activation, which is required for host defense against microorganisms. Therefore, CCP inhibition might constitute a specific treatment approach for not only myasthenia gravis but also other complement mediated autoimmune diseases.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Biesecker, G. and Gomez, C.M. (1989) Inhibition of acute passive transfer experimental autoimmune myasthenia gravis with Fab antibody to complement C6. J. Immunol. 142, 2654–2659
Carroll, M. (1999) Negative selection of self-reactive B lymphocytes involves complement. Curr. Top. Microbiol. Immunol. 246, 21–27
Christadoss, P. (1988) C5 gene influences the development of murine myasthenia gravis. J. Immunol.140, 2589–2592
Christadoss, P., Kaul, R., Shenoy, M. and Goluszko, E. (1995) Establishment of a mouse model of myasthenia gravis which mimics human myasthenia gravis pathogenesis for immune intervention. Adv. Exp. Med. Biol. 383, 195–199
De Serres, J., Groner, A. and Lindner, J. (2003) Safety and efficacy of pasteurized C1 inhibitor concentrate (Berinert P) in hereditary angioedema: a review. Transfus. Apher. Sci. 29, 247–254
De Simoni, M.G., Storini, C., Barba, M., Catapano, L., Arabia, A.M., Rossi, E. and Bergamaschini L. (2003) Neuroprotection by complement (C1) inhibitor in mouse transient brain ischemia. J. Cereb. Blood Flow. Metab. 23, 232–239
Deng, C., Goluszko, E., Tuzun, E., Yang, H. and Christadoss, P. (2002) Resistance to experimental autoimmune myasthenia gravis in IL-6-deficient mice is associated with reduced germinal center formation and C3 production. J. Immunol. 169, 1077–1083
Dickneite, G. (1993) Influence of C1-inhibitor on inflammation, edema and shock. Behring Inst. Mitt. 93, 299–305
Engel, A.G. and Fumagalli, G. (1982) Mechanisms of acetylcholine receptor loss from the neuromuscular junction. Ciba Found. Symp. 90, 197–224
Engel, A.G., Lambert, E.H. and Howard, F.M. (1977) Immune complexes (IgG and C3) at the motor end-plate in myasthenia gravis: ultrastructural and light microscopic localization and electrophysiologic correlations. Mayo Clin. Proc. 52, 267–280
Engel, A.G., Sakakibara, H., Sahashi, K., Lindstrom, J.M., Lambert, E.H. and Lennon, V.A. (1979) Passively transferred experimental autoimmune myasthenia gravis. Sequential and quantitative study of the motor end-plate fine structure and ultrastructural localization of immune complexes (IgG and C3), and of the acetylcholine receptor. Neurology 29, 179–188
Engel, A.G., Sahashi, K. and Fumagalli, G. (1981) The immunopathology of acquired myasthenia gravis. Ann. N. Y. Acad. Sci. 377, 158–174
Graus, Y.M., Verschuuren, J.J., Spaans, F., Jennekens, F., van Breda Vriesman, P.J. and De Baets, M.H. (1993) Age-related resistance to experimental autoimmune myasthenia gravis in rats. J. Immunol. 150, 4093–4103
Henze, U., Lennartz, A., Hafemann, B., Goldmann, C., Kirkpatrick, C.J. and Klosterhalfen, B. (1997) The influence of the C1-inhibitor BERINERT and the protein-free haemodialysate ACTIHAEMYL20% on the evolution of the depth of scald burns in a porcine model. Burns 23, 473–477
Howard, F.M. Jr., Lennon, V.A., Finley, J., Matsumoto, J. and Elveback, L.R. (1987) Clinical correlations of antibodies that bind, block, or modulate human acetylcholine receptors in myasthenia gravis. Ann. N. Y. Acad. Sci. 505, 526–538
Kamolvarin, N., Hemachudha, T., Ongpipattanakul, B., Phanthumchinda, K. and Sueblinvong, T. (1991) Plasma C3c in immune-mediated neurological diseases: a preliminary report. Acta. Neurol. Scand. 83, 382–387
Karachunski, P.I., Ostlie, N.S., Monfardini, C. and Conti-Fine, B.M. (2000) Absence of IFN-gamma or IL-12 has different effects on experimental myasthenia gravis in C57BL/6 mice. J. Immunol. 164, 5236–5244
Lennon, V.A., Seybold, M.E., Lindstrom, J.M., Cochrane, C. and Ulevitch, R. (1978) Role of complement in the pathogenesis of experimental autoimmune myasthenia gravis. J. Exp. Med. 147, 973–983
Poussin, M.A., Goluszko, E., Franco, J.U. and Christadoss P. (2002) Role of IL-5 during primary and secondary immune response to acetylcholine receptor. J. Neuroimmunol. 125, 51–58
Romi, F., Kristoffersen, E.K., Aarli, J.A. and Gilhus, N.E. (2005) The role of complement in myasthenia gravis: serological evidence of complement consumption in vivo. J. Neuroimmunol. 158, 191–194
Sahashi, K., Engel, A.G., Lambert, E.H. and Howard, F.M. Jr. (1980) Ultrastructural localization of the terminal and lytic ninth complement component (C9) at the motor end-plate in myasthenia gravis. J. Neuropathol. Exp. Neurol. 39, 160–172
Scott, B.G., Yang, H., Tuzun, E., Dong, C., Flavell, R.A. and Christadoss, P. (2004) ICOS is essential for the development of experimental autoimmune myasthenia gravis. J. Neuroimmunol. 153, 16–25
Tuzun, E. and Christadoss, P. (2006) Unraveling myasthenia gravis immunopathogenesis using animal models. Drug Discov Today Dis Models 3, 15–20
Tuzun, E., Scott, B.G., Goluszko, E., Higgs, S. and Christadoss, P. (2003) Genetic evidence for involvement of classical complement pathway in induction of experimental autoimmune myasthenia gravis. J. Immunol. 171, 3847–3854
Tuzun, E., Saini, S.S., Ghosh, S., Rowin, J., Meriggioli, M.N. and Christadoss, P. (2006a) Predictive value of serum anti-C1q antibody levels in experimental autoimmune myasthenia gravis. Neuromuscul. Disord. 16, 137–143
Tuzun, E., Saini, S.S., Yang, H., Alagappan, D., Higgs, S. and Christadoss, P. (2006b) Genetic evidence for the involvement of Fcgamma receptor III in experimental autoimmune myasthenia gravis pathogenesis. J. Neuroimmunol. 174, 157–167
Tuzun, E., Li, J., Saini, S.S., Yang, H. and Christadoss, P. (2007) Pros and cons of treating murine myasthenia gravis with anti-C1q antibody. J. Neuroimmunol. 182, 167–176
Vincent, A. (2006) Immunology of disorders of neuromuscular transmission. Acta Neurol. Scand. Suppl. 183, 1–7
Yang, H., Tuzun, E., Alagappan, D., Yu, X., Scott, B.G., Ischenko, A. and Christadoss, P. (2005) IL-1 receptor antagonist-mediated therapeutic effect in murine myasthenia gravis is associated with suppressed serum proinflammatory cytokines, C3, and anti-acetylcholine receptor IgG1. J. Immunol. 175, 2018–2025
Zeerleder, S., Caliezi, C., van Mierlo, G., Eerenberg-Belmer, A., Sulzer, I., Hack, C.E. and Wuillemin, W.A. (2003) Administration of C1 inhibitor reduces neutrophil activation in patients with sepsis. Clin. Diagn. Lab. Immunol. 10, 529–535
Author information
Authors and Affiliations
Corresponding authors
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Tüzün, E., Li, J., Saini, S., Yang, H., Christadoss, P. (2008). Targeting Classical Complement Pathway to Treat Complement Mediated Autoimmune Diseases. In: Lambris, J. (eds) Current Topics in Complement II. Advances in Experimental Medicine and Biology, vol 632. Springer, New York, NY. https://doi.org/10.1007/978-0-387-78952-1_19
Download citation
DOI: https://doi.org/10.1007/978-0-387-78952-1_19
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-78951-4
Online ISBN: 978-0-387-78952-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)